FDA grants cancer treatment pralatrexate orphan-drug designation

05/18/2010 | Reuters

The FDA gave orphan-drug status to pralatrexate, Allos Therapeutics' treatment for advanced or metastatic transitional cell carcinoma of the bladder. The product is in midstage development.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA